Unity Biotechnology, Inc. (NASDAQ:UBX) Sees Large Decrease in Short Interest

Unity Biotechnology, Inc. (NASDAQ:UBXGet Rating) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 694,600 shares, a decrease of 19.4% from the April 15th total of 861,800 shares. Based on an average daily volume of 632,800 shares, the short-interest ratio is presently 1.1 days. Currently, 1.4% of the company’s stock are sold short.

Shares of UBX stock opened at $0.79 on Tuesday. Unity Biotechnology has a 52-week low of $0.70 and a 52-week high of $5.09. The company has a 50-day simple moving average of $1.01 and a two-hundred day simple moving average of $1.40.

Unity Biotechnology (NASDAQ:UBXGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). On average, equities analysts expect that Unity Biotechnology will post -1.18 EPS for the current year.

Several brokerages have recently weighed in on UBX. Zacks Investment Research upgraded shares of Unity Biotechnology from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Saturday, March 19th. Citigroup decreased their target price on shares of Unity Biotechnology from $6.00 to $5.00 in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $5.61.

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC grew its position in shares of Unity Biotechnology by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 318,673 shares of the company’s stock valued at $956,000 after acquiring an additional 12,428 shares during the period. LPL Financial LLC purchased a new stake in shares of Unity Biotechnology during the 4th quarter worth approximately $26,000. BlackRock Inc. increased its stake in shares of Unity Biotechnology by 2.0% during the 3rd quarter. BlackRock Inc. now owns 900,630 shares of the company’s stock worth $2,701,000 after purchasing an additional 18,059 shares during the last quarter. GSA Capital Partners LLP increased its stake in shares of Unity Biotechnology by 4.0% during the 1st quarter. GSA Capital Partners LLP now owns 724,202 shares of the company’s stock worth $811,000 after purchasing an additional 28,087 shares during the last quarter. Finally, Walleye Capital LLC increased its stake in shares of Unity Biotechnology by 331.2% during the 4th quarter. Walleye Capital LLC now owns 54,365 shares of the company’s stock worth $79,000 after purchasing an additional 41,758 shares during the last quarter. 21.22% of the stock is owned by institutional investors and hedge funds.

About Unity Biotechnology (Get Rating)

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.

Read More

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.